Table IV.

Univariate regression analysis results for failure for PFS

Factor	Hazard Ratio	95% CI	p-value
Age*	Older, more failure	---	.25
Age < 60	1	0.77–4.70	---
Age ≥ 60	1.91	0.77–4.70	.16
Stage III†	1	0.13–1.63	---
Stage IV	0.47	0.13–1.63	.23
PS 0–1	1	---	---
PS 2–3	4.52	0.99–20.66	.05
Normal LDH‡	1	---	---
High LDH	7.41	1.97–27.80	.003
ENS 0–1	1	---	---
ENS 2–3	1.96	0.66–5.77	.22
No B Symptoms	1	---	---
B Symptoms	2.21	0.90–5.40	.08
IPI 0–1	1	---	---
IPI 2–3	5.74	1.65–19.91	.006
IPI 4–5	5.20	0.51–52.97	.16
Female	1	---	---
Male	1.21	0.27–5.18	.81
No Splenomegaly	1	---	---
Splenomegaly	2.46	0.94–6.44	.07
No BM Involvement	1	---	---
BM Involvement	0.80	0.23–2.78	.72
No GI Involvement	1	---	---
GI Involvement	1.23	0.40–3.77	.72
Hb < 12	1	---	---
Hb ≥ 12	0.47	0.18–1.23	.12
Number of Cycles of Induction Chemo*	Higher, less failure	---	.64
No Rituximab in Induction	1	---	---
Rituximab in Induction	0.28	0.12–0.69	.005
0–1 pre-ASCT Chemo	1	---	---
≥2 Chemo	4.04	1.55–10.53	.004
CR to Induction	1	---	---
PR to Induction	5.88	1.67–20.67	.006
Neither CR nor PR	16.43	3.51–76.84	.0004
CR1 at ASCT	1	---	---
PR1 at ASCT	4.69	0.94–23.32	.06
Neither CR1 nor PR1 at ASCT	7.66	1.71–34.29	.008
No Post-ASCT Rituximab	1	---	---
Post-ASCT Rituximab	0.21	0.05–0.90	.04
Group 1 (HyperCVAD )	1	---	---
Group 2 (CHOP)	3.67	0.74–18.20	.11
Group 3 (relapsed/refractory)	6.93	1.55–31.00	.01

^*Age, number of cycles, and number of pre-ASCT chemo regimens modeled as a continuous linear variable

^†No patients with Stage II disease, only one patient with Stage I disease

^‡Fourteen patients missing data, 8 (57%) have died and/or relapsed